Page 96 - 202001
P. 96

LC-MS/MS法测定肿瘤患者恶性腹水中紫杉醇的含量                                                         Δ



                                                 1 #
                                3
                                         2
               1*
                        2
        黄翠云 ,张 凤 ,柳 珂 ,陈万生 ,杨 军 (1.宜春学院化学与生物工程学院,江西 宜春 336000;2.解放军
        第二军医大学长征医院药学部,上海 200003;3.解放军第二军医大学长征医院肿瘤科,上海 200003)
        中图分类号 R969          文献标志码 A           文章编号 1001-0408(2020)01-0086-05
        DOI   10.6039/j.issn.1001-0408.2020.01.15


        摘   要   目的:建立测定肿瘤患者恶性腹水中紫杉醇含量的方法。方法:采用液相色谱-质谱联用(LC-MS/MS)技术,以文多灵为
        内标,测定肿瘤患者给予紫杉醇后恶性腹水中紫杉醇的含量,色谱柱为Zorbax SB-C18,流动相为水溶液(含0.1%甲酸和10 mmol/L
        醋酸铵)-乙腈溶液(40 ∶ 60,V/V),流速为0.25 mL/min,柱温为30 ℃,进样量为5 μL,离子源为电喷雾离子源,检测模式为多重反应
        离子监测正离子模式,干燥气温度为350 ℃,干燥气流速为10 L/min,毛细管电压为4 000 V,紫杉醇和内标在正离子模式下质荷比
        (m/z)分别为 876.5→308.0、457.3→188.1,碎片电压分别为 250、150 V,碰撞电压分别为 30、20 eV。结果:紫杉醇检测质量浓度的
        线性范围为 25~2 500 ng/mL(r =0.996 5,n=7);定量下限为 25 ng/mL;日内、日间精密度试验的 RSD 为 0.61%~3.62%(n=5、
                                 2
        3);准确度为95.34%~98.76%(n=5、3);提取回收率的RSD为3.19%~3.72%(n=3);基质效应的CV为1.52%~2.93%(n=3);
        稳定性试验的RE均小于3%(n=3)。结论:该方法简便、准确,可用于测定肿瘤患者恶性腹水中紫杉醇的含量。
        关键词     液相色谱-质谱联用;肿瘤患者;腹水;紫杉醇;含量测定


        Determination of Paclitaxel in Malignant Ascites of Tumor Patients by LC-MS/MS
        HUANG Cuiyun ,ZHANG Feng ,LIU Ke ,CHEN Wansheng ,YANG Jun (1.Chemistry and Biological
                                                                                1
                                                                   2
                                                 3
                        1
                                       2
        Engineering College,Yichun University,Jiangxi Yichun 336000,China;2.Dept. of Pharmacy,Changzheng
        Hospital, Second Military Medical University of PLA, Shanghai 200003, China;3.Dept. of Oncology,
        Changzheng Hospital,Second Military Medical University of PLA,Shanghai 200003,China)
        ABSTRACT    OBJECTIVE:To establish a method for content determination of paclitaxel in malignant ascites of tumor patients.
        METHODS:LC-MS/MS method was adopted. Using vindoline as internal standard,the content of paclitaxel in ascites of tumor
        patients was determined. The separation was performed on Zorbax SB-C18 column with mobile phase consisted of aqueous solution
        (containing 0.1% formic acid and 10 mmol/L ammonium acetate)-acetonitrile(40 ∶ 60,V/V)at the flow rate of 0.25 mL/min. the
        column temperature was 30 ℃,and sample size was 5 μL. The ion source was electrospray ion source,and the detection mode
        was multiple ion monitoring positive ion mode. MS parameters were set as following as dry gas temperature 350 ℃,dry gas flow
        rate 10 L/min,capillary voltage 4 000 V. Quantitative determination was operated in the multiple reaction monitoring(MRM)mode,
        with the ion transitions m/z 876.5→308.0 for paclitaxel and m/z 457.3→188.1 for the internal standard. The fragment voltage/
        collision energy for paclitaxel and the internal standard were 250 V/30 eV,and 150 V/20 eV,respectively. RESULTS:The linear
                                          2
        range of paclitaxel were 25-2 500 ng/mL(r =0.996 5,n=7). The lowest limit of quantitation was 25 ng/mL. RSDs of inter-day
        and intra-day precision tests were 0.61% -3.62%(n=5,3). Accuracies were 95.34% -98.76%(n=5,3). RSDs of extraction
        recovery were 3.19%-3.72%(n=3). CV of matrix effect were 1.52%-2.93%(n=3). RE of stability tests were lower than 3%(n=
        3). CONCLUSIONS:The method is simple,accurate and suitable for the content determination of paclitaxel in malignant ascites
        of tumor patients.
        KEYWORDS     LC-MS/MS;Tumor patient;Malignant ascites;Paclitaxel;Content determination



                                                                恶性肿瘤已经成为全球较大的公共卫生问题之
            Δ 基金项目:国家自然科学基金资助项目(No.81573793);上海市
                                                              [1]
        科学技术委员会科研计划项目(No.18401931600);上海市临床药学重              一 。恶性腹水是由于恶性肿瘤病变引起腹腔脏壁层腹
        点专科建设项目(No.2016-40044-002)                          膜发生弥漫性病变而导致腹腔内液体异常增多的现象,
            *药师,硕士。研究方向:临床药学。E-mail:44192977@qq.com         是恶性肿瘤晚期常见的并发症,在40%~60%的恶性腹
            # 通信作者:教授,硕士。研究方向:临床药学。E-mail:yj1961@
                                                                                        [2]
        126.com                                             水中能找到脱落的恶性肿瘤细胞 。紫杉醇是具有抗癌

         ·86  ·  China Pharmacy 2020 Vol. 31 No. 1                                   中国药房    2020年第31卷第1期
   91   92   93   94   95   96   97   98   99   100   101